New research from Memorial Sloan Kettering Cancer Center (MSK) and the Sloan Kettering Institute — MSK’s experimental research arm — explores novel predictors of immunotherapy effectiveness against lung cancer; identifies how a high-fat diet hinders intestinal damage repair; reports findings from a clinical trial for people with androgen receptor-positive salivary gland cancer; and aims to understand the impact of tumor mutational burden on patients with locally advanced non-small cell lung cancer.
Study suggests novel predictors of immunotherapy effectiveness against lung cancer
Immune checkpoint inhibitors have been a remarkable advance for the treatment of lung cancer. But most patients’ cancers either don’t respond to the treatment or the response is short-lived. A new study led by MSK medical oncologist Andrew Chow, MD, PhD, a member of the lab of co-senior author Charles Rudin, MD, PhD